Amgen Inc. $AMGN Stock: HBW Advisory Services LLC Raises Stake

HBW Advisory Services LLC grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 122.3% during the third quarter, Holdings Channel.com reports. The firm owned 4,746 shares of the medical research company’s stock after acquiring an additional 2,611 shares during the period. HBW Advisory Services LLC’s holdings in Amgen were worth $2,001,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the business. Rational Advisors Inc. raised its holdings in shares of Amgen by 13.7% in the second quarter. Rational Advisors Inc. now owns 199 shares of the medical research company’s stock valued at $72,000 after buying an additional 24 shares during the last quarter. Beacon Financial Advisory LLC grew its holdings in Amgen by 2.0% during the 2nd quarter. Beacon Financial Advisory LLC now owns 1,274 shares of the medical research company’s stock worth $461,000 after acquiring an additional 25 shares during the last quarter. Legacy Financial Advisors Inc. grew its holdings in Amgen by 0.8% during the 2nd quarter. Legacy Financial Advisors Inc. now owns 3,407 shares of the medical research company’s stock worth $1,234,000 after acquiring an additional 26 shares during the last quarter. Roman Butler Fullerton & Co. grew its holdings in Amgen by 1.4% during the 2nd quarter. Roman Butler Fullerton & Co. now owns 1,956 shares of the medical research company’s stock worth $705,000 after acquiring an additional 27 shares during the last quarter. Finally, Round Rock Advisors LLC grew its holdings in Amgen by 2.9% during the 2nd quarter. Round Rock Advisors LLC now owns 1,003 shares of the medical research company’s stock worth $363,000 after acquiring an additional 28 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Insider Activity at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 2,970 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president directly owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Rachna Khosla sold 1,252 shares of Amgen stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total transaction of $521,370.36. Following the sale, the senior vice president directly owned 6,404 shares of the company’s stock, valued at $2,666,817.72. This represents a 16.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 6,222 shares of company stock valued at $2,540,926. 0.85% of the stock is owned by corporate insiders.

Amgen Price Performance

Shares of AMGN stock opened at $426.11 on Thursday. The stock has a 50-day moving average price of $414.53 and a 200 day moving average price of $373.75. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The firm has a market cap of $230.37 billion, a price-to-earnings ratio of 26.48, a PEG ratio of 3.02 and a beta of 0.41. Amgen Inc. has a 12 month low of $288.00 and a 12 month high of $447.03.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, topping the consensus estimate of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The firm had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. During the same period in the previous year, the business posted $6.02 EPS. The company’s quarterly revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Research analysts expect that Amgen Inc. will post 22.94 EPS for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were given a dividend of $2.52 per share. The ex-dividend date was Friday, August 21st. This represents a $10.08 annualized dividend and a dividend yield of 2.4%. Amgen’s payout ratio is currently 62.65%.

Analyst Ratings Changes

A number of brokerages have weighed in on AMGN. Royal Bank Of Canada boosted their target price on shares of Amgen from $400.00 to $430.00 and gave the stock an “outperform” rating in a research note on Thursday, October 8th. Sanford C. Bernstein upped their target price on shares of Amgen from $335.00 to $345.00 and gave the stock a “market perform” rating in a research report on Thursday, August 6th. Citigroup increased their price target on shares of Amgen from $345.00 to $405.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Barclays increased their price target on shares of Amgen from $360.00 to $380.00 and gave the company an “equal weight” rating in a research note on Friday, August 14th. Finally, UBS Group raised their price target on shares of Amgen from $430.00 to $470.00 and gave the company a “buy” rating in a report on Friday, October 9th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Amgen has an average rating of “Hold” and an average price target of $387.93.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen and AstraZeneca reported positive Phase 3 results for Tezspire in eosinophilic esophagitis. Nearly 70% of patients receiving the higher dose achieved remission after 24 weeks, strengthening the drug’s expansion opportunity in a condition with limited approved treatments. What Could Amgen (AMGN) 70% Remission Trial Result Mean For Its Pipeline?
• Positive Sentiment: UBS raised its price target for Amgen to $470, signaling increased confidence in the company’s earnings and pipeline outlook. Cantor Fitzgerald also recently lifted its target to $440. UBS raises target for Amgen stock to USD 470.00 Cantor Fitzgerald raised target for Amgen stock to USD 440
• Positive Sentiment: Investors are also focusing on Amgen’s broader growth prospects, including planned Phase 3 studies for obesity drug candidate MariTide, continued manufacturing investment, and the European Union authorization of Jascayd. These developments reinforce expectations for future product launches and portfolio expansion. Amgen Gains as Investors Appear to Lean on Pipeline and Regulatory Momentum
• Positive Sentiment: Erste Group raised its FY2027 earnings-per-share estimate to $24.66 from $24.36, above Amgen’s current-year consensus estimate of $22.94. The revision suggests some analysts expect continued earnings growth.
• Neutral Sentiment: A new Phase 1 study is evaluating an alternative delivery approach for Evenity. The study could support product optimization, but it is early-stage and unlikely to materially affect near-term results. Amgen Fine-Tunes Evenity Delivery in New Phase 1 Study
• Negative Sentiment: Bank of America Securities continues to rate Amgen a Sell, providing a counterweight to the recent target increases and highlighting continued valuation or execution concerns. Bank of America Securities Remains a Sell on Amgen
• Negative Sentiment: Amgen insiders reported seven open-market sales and no purchases over the past six months. While these transactions are not necessarily company-specific signals, the absence of insider buying may temper bullish sentiment.

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.